ImmuPharma (LON:IMM) Trading Up 4.9% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report) shares were up 4.9% during trading on Saturday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.04). Approximately 109,382,164 shares were traded during trading, an increase of 245% from the average daily volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).

ImmuPharma Stock Performance

The stock’s fifty day moving average is GBX 1.40 and its 200 day moving average is GBX 1.65. The stock has a market cap of £15.30 million, a P/E ratio of -367.30 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.